FIG. 1



Rat and Dog
Human
AUC0-24 (ng.h/mL)
600,000
300,000
200,000
100,000
0
Toxicity
Activity
Dog 9mg/kg BID Day 15 (not tolerated)
STD10 Rat Female: > 240mg/kg BID
Rat 240mg/kg BID
STD10 Rat Male: > 120 and <240mg/kg BID
Rat 120mg/kg BID
HNSTD Dog 3mg/kg BID
Cohort 10: 600mg QD
Cohort 9: 400mg QD
Cohort 8: 300mg QD
Cohort 7: 200mg QD n=2
Cohort 6: 130mg QD n=2
Cohort 4: 45mg BID n=3 / Cohort 5: 90mg QD n=2
Cohort 3: 30mg BID
Cohort 2: 20mg BID
Cohort 1: 15mg BID
Projected clinically active exposure based on preclinical animal models

FIG. 2A



Compound 67A PHARMACOKINETIC PROFILES ON CYCLE 1 DAY 15/22
Plasma Concentration (ng/mL)
10000
1000
100
0
2
4
6
8
10
12
Time (h)
15mg BID
20mg BID
30mg BID
45mg BID (x̄+SD)
90mg QD (x̄+SD)
130mg QD (x̄+SD)
200mg QD (x̄+SD)

FIG. 2B



Compound 67A PLASMA AUC24 vs DOSE
Extrapolated Mean AUC24 on C1 D15/22 (ng.h/mL)
70000
60000
50000
40000
30000
20000
10000
0
0
50
100
150
200
Total Daily Dose (mg)

FIG. 3



PK Profiles for 90mg QD Food Effect Cohort on C1D1
Fasted
Fed
Mean +SD Plasma Concentration (ng/mL)
10000
1000
100
10
1
0
5
10
15
20
25
Time (h)

FIG. 4



Dose 1
Dose 2
Dose 3
Dose 4
Dose 5
Fasted
Dose 5
Fed
Dose 6
Fasted
Dose 6
Fed
Dose 7
Dose 8
+ 100 mg/ cohort until MTD
Phase 2 Expansion
Dosage
15mg BID
20mg BID
30mg BID
45mg BID
90 mg QD
90mg QD
130mg QD
130mg QD
200mg QD
300mg QD
Total
Biologically Active Exposure

FIG. 5




FIG. 6



Site
Baseline
End of Cycle 4
(45 mg BID)
End of Cycle 6
(130 mg QD)
Right Neck Lymph Nodes
Subject with relapsed/refractory follicular lymphoma

FIG. 7



Subject with Relapsed/Refractory Follicular Lymphoma
Compound 67A 30 mg
BID x two cycles

FIG. 8




Site
Baseline
D170 (Cycle 7, Day 1)
Chest Wall Posterior R Shoulder
Pleura Right Costophrenic
Subject with relapsed/refractory soft-tissue sarcoma

FIG. 9


Site
Baseline
D57 (Cycle 3, Day 1)
Pelvic/ Omental Mass
Mesenteric LN
Subject with relapsed/refractory ovarian cancer